Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
GlycoNex Logo
GlycoNex Growth Score
83
CB Rank
195848
Heat Score
82
GlycoNex develops and licenses anti-cancer monoclonal antibodies.
Founded
obfuscation
Private Taipei, T'ai-pei, Taiwan101-250 www.glyconex.com.tw
Biotechnology
Medical
Pharmaceutical
Overview

GlycoNex
Growth Score
83
Heat Score
82

Growth Score83
-8 pts
in past quarter
Heat Score 82
4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About GlycoNex

CB Rank
195848
GlycoNex develops and licenses anti-cancer monoclonal antibodies.
Founded
obfuscation
Private Taipei, T'ai-pei, Taiwan101-250 www.glyconex.com.tw
Biotechnology
Medical
Pharmaceutical

Details

Also Known As GlycoNex Inc
Operating Status Active
Company Type For Profit
Phone Number 886-2-2697-4168
Contact Email mail@glyconex.com.tw
Predictions & Insights

Growth Insight

See this Growth Insight
GlycoNex is
Lorem
 to be growing
Top Contributing Factors
Operations Expansion

Growth Prediction

See this Growth Prediction

Products & Services

GNX1021
A glycan-targeted antibody-drug conjugate (ADC) developed for treating gastric cancer by targeting specific glycans on cancer cells.
GNX201
A pro-antibody designed to improve targeting and reduce off-target effects in cancer therapy by activating only in the tumor microenvironment.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250
News

News and Press

News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 10, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 15, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,296
24.62%
 in past month

Active Website Tech Count

9GlycoNex is actively using 9 technologies for its website, according to BuiltWith. These include Common Crawl, IPhone / Mobile Compatible, and  IPv6.

Total IP

8The intellectual property of GlycoNex includes 8 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is GlycoNex's headquarters? GlycoNex is located in Taipei, T'ai-pei, Taiwan.Who are GlycoNex's competitors? Alternatives and possible competitors to GlycoNex may include AbbVie, Pfizer, and  Genmab.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d42803 1)
|